Kraig Biocraft Laboratories, a developer of spider silk-based fibers, will open a new facility in Michigan to combine its research and production efforts.
On Oct. 2, 2017, Kraig Biocraft Laboratories, a developer of spider silk-based fibers, announced the opening of a new research and production facility in Michigan. This facility will merge the company’s recombinant spider silk production operations with its research into spider silk protein technologies.
Over the 30 days following this announcement, the company will be relocating its current production operations from Indiana to its Michigan facility, and will also transfer relevant production staff to continue operations, with two new lead research positions being created to support the facility. The center will include upgraded environmental control and approximately three times the production space.
“Launching this new larger factory unifies our production and research teams’ efforts. Having our teams working hand in hand will make us more agile and open up opportunities to move technologies more quickly from the drawing board to tested and validated designs,” said Jon Rice, COO, Kraig Biocraft, in a company press release. “In addition to streamlining developmental timelines and enhancing our ability to tailor fibers, we expect to reduce R&D costs, as we generate new spider silk technologies by fully integrating design, creation, testing, and scale up, under a single roof. Our plan is to have this facility be the global central hub for spider silk technology and the center of our international operations.”
According to the company, the opening of this center will be followed by efforts to establish production centers in three overseas locations. During October 2017, the company’s management team is scheduled to meet with senior central government officials in Hanoi, Vietnam to discuss this production venture. The company is also in communication with another silk-producing country to scale its spider silk technology.
Source: Kraig Biocraft Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.